Update on BTK inhibitors for CLL: Ibrutinib pus the new kids on the block: Are they better?

Earn CME for related activities: www.naccme.com...
In this presentation from the 'Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice’ symposium, Dr. John C. Byrd provides an update on BTK inhibitors for CLL.
© 2018 Imedex, an HMP Company